cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Insmed Incorporated
2 own
4 watching
Current Price
$21.59
$-0.14
(-0.64%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
2,628.07M
52-Week High
52-Week High
28.94
52-Week Low
52-Week Low
16.41
Average Volume
Average Volume
0.96M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization2,628.07M
icon52-Week High28.94
icon52-Week Low16.41
iconAverage Volume0.96M
iconDividend Yield--
iconP/E Ratio--
What does the Insmed Incorporated do?
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.
Read More
How much money does Insmed Incorporated make?
News & Events about Insmed Incorporated.
PR Newswire
1day ago
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire BRIDGEWATER, N.J., Feb. 3, 2023 BRIDGEWATER, N.J., Feb. 3, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical...
Business Wire
9days ago
Emerald Advisers, LLC celebrated 30 years of managing client funds in 2022, and its portfolio managers and research analysts help kick off 2023 by presenting their insights and outlook for the new year at the 30th Annual Groundhog Day Investment Forum on February 2nd in King of Prussia, PA...
Ticker Report
12days ago
Insmed (NASDAQ:INSM Get Rating) had its price target cut by Barclays from $37.00 to $35.00 in a research report report published on Friday, Benzinga reports. They currently have an overweight rating on the biopharmaceutical companys stock. Other equities research analysts also ...
PR Newswire
15days ago
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire BRIDGEWATER, N.J., Jan. 20, 2023 BRIDGEWATER, N.J., Jan. 20, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical...
PR Newswire
29days ago
Insmed Provides Business Updates and Near-Term Strategic Outlook at 41st Annual J.P. Morgan Healthcare Conference Insmed Provides Business Updates and Near-Term Strategic Outlook at 41st Annual J.P. Morgan Healthcare Conference PR Newswire BRIDGEWATER, N.J., Jan. 6, 2023 Topline Data from Phase 2...
Frequently Asked Questions
Frequently Asked Questions
What is Insmed Incorporated share price today?
plus_minus_icon
Can Indians buy Insmed Incorporated shares?
plus_minus_icon
How can I buy Insmed Incorporated shares from India?
plus_minus_icon
Can Fractional shares of Insmed Incorporated be purchased?
plus_minus_icon
What are the documents required to start investing in Insmed Incorporated stocks?
plus_minus_icon
What is today’s traded volume of Insmed Incorporated?
plus_minus_icon
What is today’s market capitalisation of Insmed Incorporated?
plus_minus_icon
What is the 52-Week High and Low Range of Insmed Incorporated?
plus_minus_icon
What percentage is Insmed Incorporated down from its 52-Week High?
plus_minus_icon
What percentage is Insmed Incorporated up from its 52-Week Low?
plus_minus_icon
Current Price
$21.59
$-0.14
(-0.64%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Revance Therapeutics Inc
Revance Therapeutics Inc
$34.92
$-0.35 (-0.99 %)
Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc.
$52.57
$-1.69 (-3.11 %)
FibroGen Inc
FibroGen Inc
$24.57
$-0.28 (-1.13 %)
Blueprint Medicines Corp
Blueprint Medicines Corp
$45.65
$-3.41 (-6.95 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Revance Therapeutics Inc
Revance Therapeutics Inc
$34.92
$-0.35 (-0.99 %)
Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc.
$52.57
$-1.69 (-3.11 %)
FibroGen Inc
FibroGen Inc
$24.57
$-0.28 (-1.13 %)
Blueprint Medicines Corp
Blueprint Medicines Corp
$45.65
$-3.41 (-6.95 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00